NASDAQ:LAB • US34385P1084
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for STANDARD BIOTOOLS INC (LAB).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-11-05 | TD Cowen | Maintains | Hold -> Hold |
| 2025-02-27 | Keybanc | Downgrade | Overweight -> Sector Weight |
| 2024-10-31 | TD Cowen | Maintains | Buy -> Buy |
| 2024-08-01 | TD Cowen | Maintains | Buy -> Buy |
| 2024-04-16 | TD Cowen | Initiate | Buy |
| 2024-04-04 | Jefferies | Initiate | Buy |
| 2023-07-12 | Keybanc | Initiate | Overweight |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 106.34M 8.62% | 91.008M -14.42% | 85.331M -6.24% | 82.319M -3.53% | 84.483M 2.63% | 88.03M 4.20% | |
| EBITDA YoY % growth | -47.859M 52.69% | -70.145M -46.57% | -82.328M -17.37% | -28.28M 65.65% | -13.888M 50.89% | -10.1M 27.27% | |
| EBIT YoY % growth | -63.039M 45.75% | -87.006M -38.02% | -93.305M -7.24% | -67.064M 28.12% | -61.004M 9.04% | -53.53M 12.25% | |
| Operating Margin | -59.28% | -95.60% | -109.34% | -81.47% | -72.21% | -60.81% | |
| EPS YoY % growth | -0.85 | -0.55 35.29% | -0.20 63.64% | -0.16 19.20% | -0.15 9.37% | -0.09 37.24% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.05 27.86% | -0.04 55.11% | -0.04 60.72% | -0.03 -160.60% |
| Revenue Q2Q % growth | 17.992M -55.90% | 21.085M -49.75% | 20.324M 3.95% | 20.638M -13.27% |
| EBITDA Q2Q % growth | -9.864M 62.24% | -7.003M 54.92% | -5.925M 57.00% | -3.266M 70.17% |
| EBIT Q2Q % growth | -23.988M 20.82% | -16.059M 32.24% | -13.989M 40.39% | -12.827M 41.49% |
All data in USD
7 analysts have analysed LAB and the average price target is 1.58 USD. This implies a price increase of 60.57% is expected in the next year compared to the current price of 0.9846.
STANDARD BIOTOOLS INC (LAB) will report earnings on 2026-05-04.
The consensus EPS estimate for the next earnings of STANDARD BIOTOOLS INC (LAB) is -0.05 USD and the consensus revenue estimate is 17.99M USD.
The consensus rating for STANDARD BIOTOOLS INC (LAB) is 77.1429 / 100 . This indicates that analysts generally have a positive outlook on the stock.